Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy

被引：2

作者：

Pinato, David J. ^{[1
,2
]}

Urus, Heather ^{[1
,2
]}

Newsom-Davis, Thomas ^{[3
]}

Du Parcq, Persephone ^{[4
]}

Belessiotis, Katherine ^{[2
]}

Mapara, Leah ^{[2
]}

Gupta, Nandita ^{[5
]}

Power, Danielle ^{[2
]}

Weir, Justin ^{[5
]}

Wong, Ching Ngar ^{[1
]}

Ratnakumaran, Ragu P. ^{[2
]}

Dominy, Kathy ^{[4
]}

Khorashad, Jamshid ^{[4
]}

Bower, Mark ^{[3
]}

机构：

[1] Imperial Coll London, Dept Surg & Canc, London, England

[2] Imperial Coll NHS Trust, Charing Cross Hosp, Dept Oncol, London, England

[3] Chelsea & Westminster Hosp, Dept Oncol, London, England

[4] Hammersmith Hosp, Mol Pathol Lab, London, England

[5] Imperial Coll NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England

来源：

JOURNAL OF IMMUNOTHERAPY | 2020年 / 43卷 / 02期

基金：

英国惠康基金;

关键词：

TMB; immunotherapy; targeted; NGS; panel;

D O I：

10.1097/CJI.0000000000000295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It remains unclear whether targeted next-generation sequencing (tNGS) conveys a reliable estimate of tumor mutational burden (TMB). We sequenced 79 archival samples of immune checkpoint inhibitors (ICPIs) recipients (57% lung cancer, 43% melanoma) using Ion Ampliseq Cancer Hotspot Panel. Employing multiple cutoff values, we verified that TMB by tNGS did not correlate with response or survival following ICPI. We found enrichment of ATM mutations in ICPI-refractory tumors (P=0.01) to correlate with worse survival (4.2 vs. 10 mo, P=0.03). Limited-coverage tNGS delivers an imprecise estimate of patients' TMB but may aid identification of candidate somatic variants of predictive/prognostic significance.

引用

页码：53 / 56

页数：4

共 50 条

[21] Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
Wang, Hai-Yun
Deng, Ling
Li, Ying-Qing
Zhang, Xiao
Long, Ya-Kang
Zhang, Xu
Feng, Yan-Fen
He, Yuan
Tang, Tao
Yang, Xin-Hua
Wang, Fang
CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 973 - 982
[22] Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)
Ikeda, T.
Ohashi, K.
Sekine, A.
Ohe, Y.
Tsuda, T.
Kataoka, Y.
Hara, S.
Okamoto, N.
Kodani, M.
Matsumoto, S.
Goto, K.
ANNALS OF ONCOLOGY, 2018, 29
[23] Identification of mutational landscape predicting efficacy of immune checkpoint blockades and recurrent mutations related to high tumor mutational burden in hepatocellular carcinoma by next generation sequencing
Li, Li
Wen, Zhaohong
Overman, Michael J.
Rao, Xiaosong
Yi, Yuting
Guan, Yanfang
Liang, Jun
CANCER RESEARCH, 2019, 79 (13)
[24] Tumor mutation burden assessment on FFPE samples using a targeted next-generation sequencing assay
Chaudhary, R.
Cyanam, D.
Mittal, V.
Tom, W.
Au-Young, J.
Allen, C.
Sadis, S.
Hyland, F.
ANNALS OF ONCOLOGY, 2018, 29
[25] Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice
Lambin, S.
Lambrechts, D.
De Rop, C.
D'Haene, N.
Froyen, G.
Heukamp, L.
Huijsmans, C.
Maes, B.
Melendez, B.
Van Campenhout, C.
Vanden Bempt, I.
van den Brule, A.
Vander Borght, S.
Vannuffel, P.
Pauwels, P.
ANNALS OF ONCOLOGY, 2019, 30
[26] Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina's TruSight Oncology 500 next-generation sequencing assay
Hastings, Stephanie B.
Hariani, Gunjan
Weigman, Victor J.
Jiang, Tingting
Zhao, Chen
Raja, Rajiv
Pawlowski, Traci
Brohawn, Philip
Hurban, Patrick
CANCER RESEARCH, 2019, 79 (13)
[27] "Unburdening" Variant Review for High Tumor Mutation Burden (TMB) Cases in a Clinical Next-Generation Sequencing (NGS) Assay
Orr, C. R.
Morrissette, J.
Rosenbaum, J.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1041 - 1041
[28] Landscape of tumor mutational burden-high (TMB-high) and its correlation with immune checkpoint inhibitor biomarkers in gynecologic tumors
Huang, Richard
Lin, Douglas
Danziger, Natalie
Williams, Erik
Elvin, Julia
GYNECOLOGIC ONCOLOGY, 2021, 162 : S196 - S196
[29] Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI)
Xavier, Camila Braganca
Guardia, Gabriela
Lopes, Carlos Diego Holanda
Awni, Beatriz Mendes
Campos, Eduardo Felicio
Alves, Joao Pedro
Camargo, Anamaria Aranha
Galante, Pedro Alexandre Favoretto
Jardim, Denis L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Targeted next-generation sequencing (NGS) of 105 cancer-related genes in circulating tumor DNA (ctDNA) from patients with advanced cancers treated with immune checkpoint inhibitors (iCPI).
Call, S. Greg
Huang, Helen J.
Rodon, Jordi
Karp, Daniel D.
Tsimberidou, Apostolia M.
Naing, Aung
Janku, Filip
CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02)

← 1 2 3 4 5 →